Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry
- Language: English
- 149 Pages
- Published: February 2013
- Region: Global
The Tuberculosis Partnering 2009-2014 report provides understanding and access to the tuberculosis partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in tuberculosis partnering deals
Top tuberculosis deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type
The Tuberculosis Partnering 2009-2014 provides understanding and access to the tuberculosis partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of tuberculosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors tuberculosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 130 links to online copies of actual tuberculosis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of tuberculosis partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in tuberculosis partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading tuberculosis deals since 2009. Deals are listed by headline value, signed by bigpharma, most active of all bio pharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of tuberculosis partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of tuberculosis technologies and products.
Tuberculosis Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to tuberculosis trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
Trends in tuberculosis dealmaking in the biopharma industry since 2009
Access to summary headline, upfront, milestone and royalty data
The leading tuberculosis deals by value since 2009
In Tuberculosis Partnering 2009-2014, the available deals are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. SHOW LESS READ MORE >
Chapter 1 – Introduction
Chapter 2 – Trends in tuberculosis partnering
2.2. Tuberculosis partnering over the years
2.3. Big pharma tuberculosis dealmaking activity
2.4. Big biotech tuberculosis dealmaking activity
2.5. Most active tuberculosis dealmakers
2.6. Tuberculosis partnering by deal type
2.7. Tuberculosis partnering industry sector
2.8. Tuberculosis partnering by stage of development
2.9. Tuberculosis partnering by technology type
2.10. Disclosed financial deal terms for tuberculosis
2.10.1 Tuberculosis headline values
2.10.2 Tuberculosis upfront payments
2.10.3 Tuberculosis milestone payments
2.10.4 Tuberculosis royalty rates
Chapter 3 – Leading tuberculosis deals
3.2. Top tuberculosis deals by value
Chapter 4 – Dealmaking directory
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendix 1 – Deal type definitions
Recent report titles from
Order Form – Subscription Access Products
Table of figures
Figure 1: Tuberculosis partnering since 2009
Figure 2: Big pharma – top 50 – tuberculosis deals 2009 to 2014
Figure 3: Big pharma tuberculosis deal frequency – 2009 to 2014
Figure 4: Big biotech – top 50 – tuberculosis deals 2009 to 2014
Figure 5: Big biotech tuberculosis deal frequency – 2009 to 2014
Figure 6: Tuberculosis dealmaking activity– 2009 to 2014
Figure 7: Tuberculosis partnering by deal type since 2009
Figure 8: Tuberculosis partnering by industry sector since 2009
Figure 9: Tuberculosis partnering by stage of development since 2009
Figure 10: Tuberculosis partnering by technology type since 2009
Figure 11: Tuberculosis deals with a headline value
Figure 12: Tuberculosis deals with upfront payment values
Figure 13: Tuberculosis deals with milestone payments
Figure 14: Tuberculosis deals with royalty rates, %
Figure 15: Top tuberculosis deals by value since 2009
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co